ArticleBMC musculoskeletal disorders2026
Serum biomarkers reflecting progression of knee osteoarthritis: a stage-based evaluation of TGF-β3, ADAMTS-4, ADAMTS-5, and MMP-13.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnee osteoarthritis (KOA) is a progressive degenerative joint disease characterized by extracellular matrix (ECM) degradation and dysregulated inflammatory signaling. Identifying serum biomarkers associated with radiographic severity may improve early diagnosis, staging, and monitoring of progression.
objectiveTo evaluate stage-dependent and non-linear changes in serum transforming growth factor-β3 (TGF-β3), ADAMTS-4, ADAMTS-5, and matrix metalloproteinase-13 (MMP-13) across Kellgren–Lawrence (KL) grades of KOA.
methodsIn this cross-sectional study, 200 participants were classified into five groups according to KL grade (KL0–KL4; n = 40 per group). Individuals with systemic inflammatory, metabolic, autoimmune, renal, cardiovascular, or bone metabolism–related disorders, and those using medications affecting cartilage or bone metabolism, were excluded. After overnight fasting, serum TGF-β3, ADAMTS-4, ADAMTS-5, and MMP-13 levels were measured by ELISA. Between-group comparisons were performed using one-way ANOVA or Kruskal–Wallis tests with appropriate post-hoc analyses, and data are presented as mean ± standard deviation, unless otherwise stated.
resultsADAMTS-4 differed significantly across KL grades (overall p < 0.00001), showing a non-linear pattern with higher levels in KL1–KL3. ADAMTS-5 demonstrated a pronounced stage-dependent pattern (overall p < 0.00002), peaking in KL1 and declining toward advanced stages. Serum MMP-13 levels did not differ significantly across KL grades (p > 0.05). TGF-β3 levels differed significantly across KL grades (overall p = 0.0015), with lower levels in KL1–KL2 compared with KL0 and intermediate levels in KL3–KL4.
conclusionsADAMTS-4 and ADAMTS-5 exhibit biphasic, stage-dependent changes during KOA progression, consistent with early enzymatic activation followed by late-stage reduction. Early declines in TGF-β3 may reflect impaired cartilage homeostasis. The observed non-linear, stage-dependent serum patterns—particularly for ADAMTS-4, ADAMTS-5, and TGF-β3—highlight dynamic extracellular matrix remodeling during KOA progression and support the potential value of serum biomarkers as adjuncts to radiographic staging, especially in early disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.